Fungi Bioactive Metabolites : Integration of Pharmaceutical Applications

• Autore: Deshmukh Sunil Kumar
• Pubblicazione: Singapore : , : Springer, , 2024; ©2024
• Edizione: 1st ed.
• Descrizione fisica: 1 online resource (759 pages)
• Disciplina: 572.829
• Altri autori: TakahashiJacqueline Aparecida SaxenaSanjai
• Nota di contenuto: Intro -- Preface -- Contents -- Editors and Contributors -- Part I: Bioactive Compounds from Endophytic Fungi -- Chapter 1: Recent Advances in Pharmaceutically Important Compounds from Endophytic Fungi -- 1 Introduction -- 2 Biomes, Regions, and Plant Families -- 3 Handling Endophytic Fungi -- 4 Innovative Pharmacological Targets for Bioactive Fungal Metabolites -- 5 Promising Endophytic Fungi Metabolites Recently Described -- 6 Developments Related to Bioactive Metabolites from Endophyte Fungi -- 7 Perspectives -- References -- Chapter 2: Recent Advances in Anti-Infective Compounds Produced by Endophytic Fungi -- 1 Introduction -- 2 Role of Endophytic Research with Respect to Drug Discovery -- 3 Antibacterial Metabolites -- 3.1 Antimycobacterial Compounds from Endophytes -- 4 Antifungal Metabolites -- 5 Antiviral Metabolites -- 6 Antiprotozoal Metabolites -- 6.1 Antimalarial Metabolites -- 6.2 Anti-Leishmanial Metabolites -- 6.3 Anti-Trypanosomal Metabolites -- 7 Future Prospects and Challenges -- References -- Chapter 3: Fungal Endophytes: An Accessible Natural Repository for Discovery of Bioactive Compounds -- 1 Endophytic Natural Products (ENPs): An Introduction -- 1.1 Endophytes as a Treasure Hunt for ENPs -- 1.2 Polyketides, an Important Class of Bioactive ENPs -- 1.3 Small Peptides as Bioactive ENPs -- 2 ENPs with Anticancer Potential -- 3 ENPs with Antimicrobial Potential -- 4 Molecular Crosstalk Underlying ENPs Production -- 5 Conclusion -- References -- Part II: Endolichenic Fungi: a Source of New Chemical Entities -- Chapter 4: Endolichenic Fungi as a Source of Pharmaceutically Active Compounds -- 1 Introduction -- 2 Pharmaceutically Active Compounds Isolated from Endolichenic Fungi -- 2.1 Cytotoxic Compounds Isolated from Endolichenic Fungi -- 2.2 Antifungal Compounds Isolated from Endolichenic Fungi. ; 2.3 Antioxidant Compounds Isolated from Endolichenic Fungi -- 2.4 Antibacterial Compounds Isolated from Endolichenic Fungi -- 2.5 Antiviral Compounds Isolated from Endolichenic Fungi -- 2.6 Anti-Inflammatory Compounds Isolated from Endolichenic Fungi -- 3 Classification of Bioactive Compounds According to Selected Taxa of Their Endolichenic Fungi -- 4 Summary Statement -- References -- Chapter 5: Endolichenic Fungi, an Emerging Source of Bioactive Compounds: A Pharmaceutical Perspective -- 1 Introduction -- 2 Anticancer Compounds -- 3 Anti-Microbial Compounds -- 3.1 Antibacterial Compounds -- 3.2 Antifungal Compounds -- 4 Anti-Inflammatory Compounds -- 5 Anti-Alzheimer Compounds -- 6 Antioxidant Compounds -- 7 AChE Inhibitors -- 8 Phytotoxic Compounds -- 9 Antithrombotic Compounds -- 10 Conclusion -- References -- Part III: Marine Fungi as a Source of Medicinal Compounds -- Chapter 6: Antibiofilm Metabolites from Sponge-Derived Aspergillus, Penicillium, and Fusarium for the Antibiotic Pipeline -- 1 Introduction -- 1.1 Antibiofilm Mechanism of Action Versus Antibiotic Resistance -- 1.2 Marine Sponge Symbionts as a Potential Source of Antimicrobials -- 2 Secondary Metabolites and New Potential Antibiotics -- 2.1 Antimicrobials -- 2.1.1 Aspergillus Antimicrobial Metabolites -- 2.1.2 Penicillium Antimicrobial Metabolites -- 2.1.3 Fusarium Antimicrobial Metabolites -- 2.2 Antibiofilms -- 2.2.1 Aspergillus Antibiofilm Metabolites -- 2.2.2 Penicillium Antibiofilm Metabolites -- 2.2.3 Fusarium Antibiofilm Metabolites -- 3 Global Distribution of Antibacterial Sponge-Derived Fungal Metabolites -- 3.1 Antibacterial -- 3.2 Antibacterial Sponge-Derived Penicillium Metabolites -- 3.3 Antibacterial Sponge-Derived Fusarium Metabolites -- 4 Bioprospecting Antibiofilm Metabolites -- 4.1 What Is Bioprospecting? -- 4.2 Methods Used for Bioprospecting. ; 5 Summary and Conclusion -- References -- Untitled -- Chapter 7: Marine Fungi as a Bioresource of Medicinal Entities -- 1 Introduction -- 2 Sources of Marine Fungi -- 2.1 Plant Sources -- 2.1.1 Marine Algae and Seaweeds -- 2.2 Animal Sources -- 2.2.1 Sponges -- 2.2.2 Corals -- 2.2.3 Sea Urchins -- 2.2.4 Marine Vertebrates: Fish -- 2.3 Mangrove Soil -- 2.4 Marine Sediment -- 3 How Can Marine Fungal Compounds Serve as Novel Drugs? -- 4 Challenges and Future Aspects -- 4.1 Untapping the Potential of Marine Fungi -- 4.2 Quantity of Secondary Metabolites Produced. -- 4.3 Understanding of Complete Secondary Metabolites Synthesis Pathway in Marine Fungi -- 4.4 Sustainable Drug Delivery -- 4.5 Industrial Transition and Commercialization -- 5 Conclusions -- References -- Chapter 8: Natural Bioactive Products from Marine Fungi Against Bacterial Infection -- 1 Introduction -- 2 Fungal Secondary Metabolites Biosynthetic Pathway -- 3 Bioactive Compounds Derived from Marine Fungi -- 4 Marine-Derived Fungi Effective Against Different Bacterial Pathogens -- 4.1 Marine-Derived Compounds Effective to Gram-Positive Bacterial Pathogens -- 4.2 Marine-Derived Fungal Compounds Effective Against Gram-Negative Bacteria -- 4.3 Broad-Spectrum Antimicrobial Effect of Marine-Derived Fungal Secondary Metabolites -- 4.4 Marine-Derived Fungal Secondary Metabolites Effective Against Multidrug Resistant Bacterial Strains -- 5 Conclusion -- 6 Future Prospects -- References -- Part IV: Fungi as a Bioresource of Pharmacologically Active Agents -- Chapter 9: Penicillium: A Treasure Trove for Antimycobacterial and Antioxidant Metabolites -- 1 Introduction -- 2 Antimycobacterial Activity of Penicillium -- 3 Antioxidant Activity of Penicillium -- 4 Biotechnological Interventions in Penicillium for Enhanced Metabolite Production -- 4.1 Antimycobacterial Potential -- 4.2 Antioxidant Potential. ; 5 Conclusion -- References -- Chapter 10: Metabolites from Fungi: A Promising Source of Lead Compounds Against Cancer -- 1 Historical Overview: Discovery of Anticancer Drugs from Fungi -- 2 Promising Fungal Metabolites and Derivatives with Anticancer Effects -- 2.1 Edible and Medicinal Mushrooms -- 2.2 Endophytic Fungi -- 2.3 Fungi from Other Biomes -- 3 Future Perspectives: What´s Next in the Pathway of Anticancer Drug Discovery from Fungal Compounds -- 4 Final Considerations -- References -- Chapter 11: Edible Mushrooms Substances as Natural Prevention in Autoimmunological Diseases -- 1 Introduction -- 2 Primary Metabolites: Significant Developments -- 2.1 Carbohydrates -- 2.2 Amino Acids and Proteins -- 2.3 Glycoproteins: Lectins -- 2.4 Lipids -- 3 Secondary Metabolites: Significant Developments -- 3.1 Phenolic Compounds -- 3.2 Indole Compounds -- 3.3 Vitamins -- 3.4 Isoprenoids -- 3.5 Bioelements -- 4 Conclusions -- References -- Chapter 12: New Antifungal Drugs: Discovery and Therapeutic Potential -- 1 Introduction -- 2 Target Fungal Cell Wall and Membrane Synthesis -- 2.1 Fosmanogepix/Manogepix (A Novel Gwt1 Enzyme Inhibitor, AMPLYX) -- 2.1.1 Mechanism of Action -- 2.1.2 Spectrum of Activity -- 2.1.3 Mouse Model Studies -- 2.1.4 Clinical Studies -- 2.2 Ibrexafungerp (An Enfumafungin Derivative, Glucan Synthase Inhibitor, Scynexis) -- 2.2.1 Mechanism of Action -- 2.2.2 Spectrum of Activity/in Vivo Susceptibility Data -- 2.2.3 Clinical Development -- 2.3 Rezafungin (Second-Generation Echinocandins, CIDARA) -- 2.3.1 Mechanism of Action -- 2.3.2 Spectrum of Activity/In Vivo Susceptibility Data -- 2.3.3 Clinical Development -- 2.4 Encochleated Amphotericin B (MAT2203, CAmB-MATINAS, Cell Membrane Inhibitor) -- 2.4.1 Mechanism of Action -- 2.4.2 Spectrum of Activity/In Vivo Susceptibility Data -- 2.4.3 Clinical Development -- 3 Tetrazole Inhibitors. ; 3.1 Oteseconazole (VT-1161), VT-1598, VT-1129 (Mycovia, Novel Tetrazole-Specific Cyp51 Inhibitors) -- 3.1.1 Mechanism of Action and Spectrum of Activity/In Vivo Susceptibility Data -- 3.1.2 Clinical Development -- 3.2 Opelconazole (PC945, Pulmocide, Novel Tetrazole-Specific Cyp51 Inhibitors) -- 3.2.1 Mechanism of Action -- 3.2.2 Spectrum of Activity/In Vivo Susceptibility Data -- 3.2.3 Clinical Development -- 4 Target Nucleic Acid Metabolism -- 4.1 Olorofim (F2G, LTD, a Novel Dihydroorotate Dehydrogenase Enzyme Inhibitor) -- 4.1.1 Mechanism of Action -- 4.1.2 Spectrum of Activity/In Vivo Susceptibility Data -- 4.1.3 Clinical Data -- 5 Final Evaluation -- References -- Chapter 13: Fungal Enzyme Inhibitors: Potent Repository of Lead Compounds to Curb Cancer -- 1 Introduction -- 1.1 Cancer -- 1.2 Rationale of Selecting Enzyme Inhibitors for Anticancer Therapy -- 2 Selective Enzyme Targets for Discovering Endophytic Fungal Inhibitors -- 2.1 DNA Topoisomerases -- 2.2 Telomerase -- 2.3 Angiotensin-Converting Enzyme (ACE) -- 2.4 Histone Deacetylase (HDAC) -- 2.5 DNA Polymerase -- 2.6 Methionine Aminopeptidase 2 (Met AP-2) -- 2.7 Caspase-1 -- 2.8 Cyclooxygenase (COX) -- 2.9 Phosphatidylinositol 3′ Kinases (PI3Ks) -- 3 Concluding Remarks -- References -- Chapter 14: Bioactive Metabolites from Fungi with Anti-Inflammatory and Antithrombotic Properties: Current Status and Future P... -- 1 Introduction -- 2 Fungi as Sustainable Sources for Bioactive Compounds of Natural Origin -- 3 Fungi Bioactive Metabolites with Anti-Inflammatory and Antithrombotic Properties as Candidates for the Development of Supple... -- 3.1 Fungi-Derived Vitamins and Bioactive Carotenoid-Based Colored Pigments -- 3.2 Fungi-Derived Classic and Complex Bioactive Phenolic Compounds/Pigments with Anti-Inflammatory and Antithrombotic Properti. ; 3.3 Fungi Lipid Bioactives with Anti-Inflammatory and Antithrombotic Properties.
• Titolo autorizzato: Fungi Bioactive Metabolites
• ISBN: 981-9956-96-X
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Lingua di pubblicazione: Inglese
• Record Nr.: 9910842298903321
• Lo trovi qui: Univ. Federico II